Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia

Leukemia-initiating cells of core binding factor (CBF) acute myeloid leukemia (AML) likely derive from early committed hematopoietic precursors expressing CD33. As such, targeting CD33 could ameliorate the chance of cure of CBF AML patients. We compared 12 CBF AML patients treated with Fludarabine,...

Full description

Bibliographic Details
Main Authors: Michele Gottardi, Federico Mosna, Sergio De Angeli, Cristina Papayannidis, Anna Candoni, Marino Clavio, Cristina Tecchio, Andrea Piccin, Marta Campo dell’Orto, Fabio Benedetti, Giovanni Martinelli, Filippo Gherlinzoni
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:Hematology Reports
Subjects:
Core binding factor
acute myeloid leukemia
gemtuzumab ozogamicin
immunotherapy
autologous stem cell transplantation
Online Access:http://www.pagepress.org/journals/index.php/hr/article/view/7028

Internet

http://www.pagepress.org/journals/index.php/hr/article/view/7028

Similar Items